Biotech, emerging markets are big VC targets

Auditing firm KPMG surveyed 350 venture capitalists, entrepreneurs, corporate buyers, investment bankers and research analysts on trends in venture capital over the next two years. According to the group's findings, greentech/cleantech will receive the most funding, with biotech and pharma coming in second. Almost half of respondents also said that they expect rising merger and acquisition activity in the next year.

Emerging markets are also looking good to investors. Sixty-four percent said China and India will garner an increasingly large slice of the VC pie. "Globalization...has VC investors concentrating heavily on capturing emerging-market opportunities, particularly in Asia, while looking for the next-best-thing in eco friendly and medical technologies," said Packy Kelly, KPMG partner and co-leader of its venture capital practice.

- see this release for more

Related Articles:
Serial investors: Comforting figures for VC backers. Report
VC adds billions in its pursuit of biotech ventures. Report
Billion-dollar baby: Biotech still on a roll with VC funds. Report

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.